Abstract：
UNASSIGNED: Insulinomas are the most common functional pancreatic neuroendocrine tumors (PNETs) that lead to incapacitating hypoglycemia. Guidelines recommend surgical resection as the mainstay of management. However, surgery is fraught with complications, causing significant peri/post-operative morbidity. Since insulinomas are usually benign, solitary, small (<2 cm), and do not need lymphadenectomy, hence, in this regard, endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is now being increasingly performed, to circumvent these adverse events and impairment of pancreatic function.
UNASSIGNED: A comprehensive literature search was undertaken across various databases (PubMed/MEDLINE, Embase, Scopus), with no language restriction, for relevant articles (case series, reviews, case reports) pertaining to EUS-RFA for insulinoma and PNETs, till October 2023. In this review, we have explicated the role of EUS-RFA for insulinoma management, detailing thoroughly its mechanism of action, EUS-RFA devices with data on its safety and efficacy, and an algorithmic approach for its management.
UNASSIGNED: EUS-RFA is being advocated as a \'mini-invasive\' option with the potential to replace surgery as a first-line approach for benign, sporadic, solitary, and small (<2 cm) insulinomas. Under real-time guidance, EUS-RFA has immense precision, is safe, predictable, with acceptable safety profile. Presently, it is being frequently performed for high-risk or inoperable candidates. Current need-of-the-hour is a randomized controlled trial to substantiate its role in the therapeutic algorithm for insulinoma management.
UNASSIGNED: A comprehensive literature search was undertaken across various databases (PubMed/MEDLINE, Embase, Scopus), with no language restriction, for relevant articles (case series, reviews, case reports) pertaining to EUS-RFA for insulinoma and PNETs, till October 2023. In this review, we have explicated the role of EUS-RFA for insulinoma management, detailing thoroughly its mechanism of action, EUS-RFA devices with data on its safety and efficacy, and an algorithmic approach for its management.
UNASSIGNED: EUS-RFA is being advocated as a \'mini-invasive\' option with the potential to replace surgery as a first-line approach for benign, sporadic, solitary, and small (<2 cm) insulinomas. Under real-time guidance, EUS-RFA has immense precision, is safe, predictable, with acceptable safety profile. Presently, it is being frequently performed for high-risk or inoperable candidates. Current need-of-the-hour is a randomized controlled trial to substantiate its role in the therapeutic algorithm for insulinoma management.
摘要：
■胰岛素瘤是最常见的功能性胰腺神经内分泌肿瘤（PNETs），可导致失能性低血糖。指南建议将手术切除作为管理的主要手段。然而,手术充满并发症,导致显著的围手术期/术后发病率。由于胰岛素瘤通常是良性的，孤独，小（<2厘米），也不需要淋巴结清扫术,因此，在这方面,内镜超声引导下的射频消融（EUS-RFA）现在越来越多，规避这些不良事件和胰腺功能受损。
■在各种数据库中进行了全面的文献检索(PubMed/Medline，Embase,Scopus),没有语言限制，对于相关文章(案例系列，reviews,病例报告)与胰岛素瘤和PNETs的EUS-RFA有关，直到2023年10月。在这次审查中,我们已经阐明了EUS-RFA在胰岛素瘤治疗中的作用，彻底详述其作用机制，EUS-RFA设备及其安全性和有效性数据，以及其管理的算法方法。
■EUS-RFA被提倡为“微型侵入性”选项，有可能取代手术作为良性疾病的一线治疗方法，零星的,孤独，和小（<2厘米）胰岛素瘤。在实时指导下,EUS-RFA具有极高的精度,是安全的,可预测的,具有可接受的安全性。目前,它经常被用于高风险或无法操作的候选人。当前的小时需求是一项随机对照试验，以证实其在胰岛素瘤治疗算法中的作用。
■在各种数据库中进行了全面的文献检索(PubMed/Medline，Embase,Scopus),没有语言限制，对于相关文章(案例系列，reviews,病例报告)与胰岛素瘤和PNETs的EUS-RFA有关，直到2023年10月。在这次审查中,我们已经阐明了EUS-RFA在胰岛素瘤治疗中的作用，彻底详述其作用机制，EUS-RFA设备及其安全性和有效性数据，以及其管理的算法方法。
■EUS-RFA被提倡为“微型侵入性”选项，有可能取代手术作为良性疾病的一线治疗方法，零星的,孤独，和小（<2厘米）胰岛素瘤。在实时指导下,EUS-RFA具有极高的精度,是安全的,可预测的,具有可接受的安全性。目前,它经常被用于高风险或无法操作的候选人。当前的小时需求是一项随机对照试验，以证实其在胰岛素瘤治疗算法中的作用。
